Luye Pharma Group Ltd. (HKG:2186)
1.970
+0.020 (1.03%)
May 12, 2025, 4:08 PM HKT
Luye Pharma Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 471.89 | 532.61 | 604.81 | -134.39 | 706.59 | Upgrade
|
Depreciation & Amortization | 783.39 | 693.73 | 663.46 | 577 | 506.27 | Upgrade
|
Other Amortization | 7.28 | 8.12 | 7.86 | 4.99 | 6.35 | Upgrade
|
Loss (Gain) From Sale of Assets | -18.49 | -1.5 | 0.21 | -11.36 | -0.09 | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | 11.47 | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | -1.79 | -1.94 | -1.55 | 14.81 | 3.46 | Upgrade
|
Loss (Gain) on Equity Investments | 0.77 | -0.79 | -0.83 | -10.27 | -1.73 | Upgrade
|
Stock-Based Compensation | 21.5 | 20.64 | 25.45 | 49.98 | 50.9 | Upgrade
|
Other Operating Activities | 136.97 | -53.37 | 23.14 | 109.71 | 62.02 | Upgrade
|
Change in Accounts Receivable | -424.88 | -570.84 | -18.77 | -211.76 | 145 | Upgrade
|
Change in Inventory | -84.03 | -54.92 | -26.6 | -134.04 | 4.88 | Upgrade
|
Change in Accounts Payable | -77.89 | 207.24 | -10.95 | 43.64 | 144.21 | Upgrade
|
Change in Unearned Revenue | 9.97 | -74.87 | -42.47 | -6.43 | -16.86 | Upgrade
|
Change in Other Net Operating Assets | -656.92 | 891.38 | 418.57 | -109.49 | -577.56 | Upgrade
|
Operating Cash Flow | 167.76 | 1,595 | 1,654 | 182.37 | 1,033 | Upgrade
|
Operating Cash Flow Growth | -89.48% | -3.53% | 806.83% | -82.35% | -27.36% | Upgrade
|
Capital Expenditures | -594.07 | -632.66 | -655.68 | -556.2 | -692.81 | Upgrade
|
Sale of Property, Plant & Equipment | 7.44 | 3.17 | 5.66 | 13.77 | 2.31 | Upgrade
|
Divestitures | -0.02 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -1,113 | -532.61 | -507.68 | -985.4 | -732.03 | Upgrade
|
Investment in Securities | 536.35 | -511.14 | -675.93 | -2,057 | 1,295 | Upgrade
|
Other Investing Activities | 162.36 | 254.97 | 175.32 | 148.46 | 266.1 | Upgrade
|
Investing Cash Flow | -1,471 | -1,418 | -1,658 | -3,436 | 138.2 | Upgrade
|
Short-Term Debt Issued | - | 4.96 | 10.1 | - | - | Upgrade
|
Long-Term Debt Issued | 10,119 | 8,077 | 7,656 | 7,155 | 7,353 | Upgrade
|
Total Debt Issued | 10,119 | 8,082 | 7,666 | 7,155 | 7,353 | Upgrade
|
Short-Term Debt Repaid | - | -15.06 | - | - | - | Upgrade
|
Long-Term Debt Repaid | -8,263 | -8,555 | -8,323 | -7,561 | -5,913 | Upgrade
|
Total Debt Repaid | -8,263 | -8,570 | -8,323 | -7,561 | -5,913 | Upgrade
|
Net Debt Issued (Repaid) | 1,856 | -488.07 | -656.23 | -406.32 | 1,440 | Upgrade
|
Issuance of Common Stock | - | 922.97 | - | 1,044 | - | Upgrade
|
Repurchase of Common Stock | - | - | - | - | -77.96 | Upgrade
|
Common Dividends Paid | - | - | - | - | -175.49 | Upgrade
|
Other Financing Activities | 1,101 | 406.7 | 710.38 | 1,241 | -932.61 | Upgrade
|
Financing Cash Flow | 2,956 | 841.6 | 54.15 | 1,879 | 253.98 | Upgrade
|
Foreign Exchange Rate Adjustments | 45.41 | -103.6 | -164.15 | -52.37 | 112.41 | Upgrade
|
Net Cash Flow | 1,698 | 915.23 | -114.51 | -1,427 | 1,538 | Upgrade
|
Free Cash Flow | -426.31 | 962.83 | 998.11 | -373.83 | 340.64 | Upgrade
|
Free Cash Flow Growth | - | -3.54% | - | - | -19.53% | Upgrade
|
Free Cash Flow Margin | -7.03% | 15.67% | 16.69% | -7.19% | 6.15% | Upgrade
|
Free Cash Flow Per Share | -0.11 | 0.26 | 0.29 | -0.11 | 0.11 | Upgrade
|
Cash Interest Paid | 450.1 | 471.51 | 369.2 | 297.12 | 330.36 | Upgrade
|
Cash Income Tax Paid | 206.93 | 132.23 | 92.77 | 270.74 | 160.41 | Upgrade
|
Levered Free Cash Flow | -2,501 | 629.06 | -43 | -778.54 | 499.72 | Upgrade
|
Unlevered Free Cash Flow | -2,150 | 1,051 | 251.85 | -528.88 | 763 | Upgrade
|
Change in Net Working Capital | 1,966 | -939.34 | -225.24 | -153.53 | -1,008 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.